Zacks Investment Research downgraded shares of Aemetis (NASDAQ:AMTX) from a buy rating to a hold rating in a research note published on Monday morning.

According to Zacks, “Aemetis, Inc. is an advanced fuels and renewable chemicals company. It produces renewable chemicals and fuels using patented microbes and processes. Aemetis owns and operates an ethanol animal feed plant in California to produce D5 Advanced Biofuels using the sorghum/biogas/CHP pathway. The Company also built, owns, and operates a renewable chemicals and advanced fuels production facility on the East Coast of India producing high quality, distilled biodiesel and refined glycerin for customers in Europe and Asia. Aemetis, Inc. is headquartered in Cupertino, California. “

Separately, B. Riley set a $2.00 price objective on shares of Aemetis and gave the stock a hold rating in a research note on Monday, August 13th.

Shares of NASDAQ AMTX opened at $1.01 on Monday. Aemetis has a 12 month low of $0.45 and a 12 month high of $3.12. The company has a debt-to-equity ratio of -1.53, a current ratio of 0.27 and a quick ratio of 0.11.

Aemetis (NASDAQ:AMTX) last issued its quarterly earnings data on Thursday, August 9th. The specialty chemicals company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.07. The firm had revenue of $45.03 million for the quarter, compared to analyst estimates of $42.51 million. As a group, research analysts forecast that Aemetis will post -1.4 earnings per share for the current fiscal year.

Aemetis Company Profile

Aemetis, Inc operates as a renewable fuels and bio-chemicals company in North America and India. The company focuses on the acquisition, development, and commercialization of various technologies that replace traditional petroleum-based products by the conversion of ethanol and biodiesel plants into advanced bio refineries.

Featured Article: Diversification For Individual Investors

Get a free copy of the Zacks research report on Aemetis (AMTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.